Search for terms    x       Skip to Main Content            COVID-19 is an emerging, rapidly evolving situation.
 Get the latest public health information from CDC: https://www.coronavirus.gov.
 Get the latest research information from NIH:  https://www.nih.gov/coronavirus.
 ×  Find Studies  New Search Advanced Search See Studies by Topic See Studies on Map How to Search How to Use Search Results How to Find Results of Studies How to Read a Study Record   About Studies  Learn About Studies Other Sites About Studies Glossary of Common Site Terms   Submit Studies  Submit Studies to ClinicalTrials.gov PRS Why Should I Register and Submit Results?
 FDAAA 801 and the Final Rule How to Apply for a PRS Account How to Register Your Study How to Edit Your Study Record How to Submit Your Results Frequently Asked Questions Support Materials Training Materials   Resources  Selected Publications Clinical Alerts and Advisories RSS Feeds Trends, Charts, and Maps Downloading Content for Analysis   About Site  What's New ClinicalTrials.gov Background About the Results Database History, Policies, and Laws ClinicalTrials.gov Modernization Media/Press Resources Linking to This Site Terms and Conditions Disclaimer   PRS Login        Find Studies  New Search Advanced Search See Studies by Topic See Studies on Map How to Search How to Use Search Results How to Find Results of Studies How to Read a Study Record   About Studies  Learn About Studies Other Sites About Studies Glossary of Common Site Terms   Submit Studies  Submit Studies to ClinicalTrials.gov PRS Why Should I Register and Submit Results?
 Please remove one or more studies before adding more.
 LIBERATE Trial in COVID-19 (LIBERATE)              The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.
 Listing a study does not mean it has been evaluated by the U.S. Federal Government.
 Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
 Read our disclaimer for details.
 ClinicalTrials.gov Identifier: NCT04334629    Recruitment Status :       Recruiting                First Posted : April 6, 2020  Last Update Posted : October 23, 2020  See   Contacts and Locations        Sponsor:  King's College London  Collaborator: Guy's &amp; St Thomas NHS Foundation Trust Information provided by (Responsible Party): King's College London     Study Details   Tabular View No Results Posted Disclaimer How to Read a Study Record         Study Description   Go to      Top of Page Study Description Study Design  Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information     Brief Summary: The study aims to evaluate the reduction in severity and progression of lung injury with three doses of lipid ibuprofen in patients with SARS-CoV-2 infections.
 Condition or disease   Intervention/treatment   Phase     Coronavirus Respiratory Distress Syndrome SARS-CoV Infection   Drug: Ibuprofen   Phase 4       Study Design   Go to      Top of Page Study Description Study Design  Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information      Layout table for study information          Study Type : 
   Interventional
      (Clinical Trial)
     
   
      Estimated
 Enrollment : 230 participants   Allocation: Randomized   Intervention Model: Parallel Assignment   Masking:  Double (Investigator, Outcomes Assessor)   Primary Purpose:  Treatment    Official Title: Lipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19: a Multicentre, Randomised, Controlled Trial    Actual Study Start Date : May 26, 2020    Estimated Primary Completion Date : May 25, 2021    Estimated Study Completion Date : September 25, 2021        Resource links provided by the National Library of Medicine      Drug Information available for:
  	 	 	Ibuprofen Ibuprofen sodium Ibuprofen lysine Midol    Genetic and Rare Diseases Information Center resources:
  	 	 	Respiratory Distress Syndrome, Infant Acute Respiratory Distress Syndrome Severe Acute Respiratory Syndrome     U.S. FDA Resources        Arms and Interventions   Go to      Top of Page Study Description Study Design  Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information          Arm   Intervention/treatment      
    No Intervention: Standard of care
        
    Experimental: Standard of care plus lipid ibuprofen
    
       Drug: Ibuprofen Lipid ibuprofen 200 mg Other Name: Flarin          Outcome Measures   Go to      Top of Page Study Description Study Design  Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information        Primary Outcome Measures :
    Disease progression [ Time Frame: 14 days ]Worsening respiratory failure; defined using severity of hypoxaemia using [PaO2/FiO2 ratio OR SpO2/FiO2 ratio] Time to mechanical ventilation [ Time Frame: 14 days ]Time to mechanical ventilation (or need of)      Secondary Outcome Measures :
    Overall survival [ Time Frame: 28 days ] Reduction in proportion of patients who require ventilation [ Time Frame: 28 days ] Reduction in length of Critical Care stay [ Time Frame: 28 days ] Reduction in length of Hospital stay [ Time Frame: 28 days ] Modulation of serum pro- and anti-inflammatory cytokines [ Time Frame: 28 days ] Reduction in duration of ventilation [ Time Frame: 28 days ] Increase in ventilator-free days [ Time Frame: 28 days ]        Eligibility Criteria   Go to      Top of Page Study Description Study Design  Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information       Information from the National Library of Medicine    Choosing to participate in a study is an important personal decision.
 Talk with your doctor and family members or friends about deciding to join a study.
 To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below.
 For general information, Learn About Clinical Studies.
 Layout table for eligibility information         Ages Eligible for Study:    18 Years and older   (Adult, Older Adult)   Sexes Eligible for Study:    All   Accepts Healthy Volunteers:    No    Criteria Inclusion Criteria:  Male or female patients aged 18 years and above; Hospitalised; Confirmed or suspected SARS-CoV-2 infection; National Early Warning Score (NEWS2) greater than or equal to 3 in a single parameter or NEWS2 &gt; 5 overall; Acute hypoxemic respiratory failure: PaO2/FiO2 ratio less than or equal to 300 OR SpO2/FiO2 ratio &lt; 315 (Kigali Modification) Provision of written informed consent by the patient OR by the patient's Legal Representative OR professional consultee.
 Exclusion Criteria:   Any of the following contraindications to ibuprofen:  A known hypersensitivity to ibuprofen or any other constituent of the medicinal product; Patients who have previously shown hypersensitivity reactions (e.g.
 asthma, rhinitis, angioedema or urticaria) in response to aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs); Patients with a history of, or existing gastrointestinal ulceration/perforation or bleeding, including that associated with NSAIDs; Patients with severe hepatic failure; Patients with acute renal failure; Patients with severe heart failure.
 Participation in any other investigational drug products less than 30 days prior to study enrolment; Glasgow Coma Score &lt; 12; Patients who cannot swallow oral capsules; Pregnant or lactating women; Any medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial.
 Contacts and Locations   Go to      Top of Page Study Description Study Design  Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information        Information from the National Library of Medicine    
  To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
